Product Information
CRINONE 8% GEL is a brand product labeled by Allergan, Inc., priced at $27.9726 per GM under NDC 00023615108. Its NADAC has been published 146 times since Sep 25, 2019.
FDA first approved this application on Jul 31, 1997.
The High Outlier badge above means this manufacturer's average price in the progesterone market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
90 mg/1.125g
Manufacturer
Allergan, Inc.NDC
00023615108
Classification
Brand
Dosage Form
GEL
Route
VAGINAL
Effective Date
9/23/2026
Active Ingredients
PROGESTERONEApproval Type
New Drug (NDA)
FDA Application
NDA020701FDA Approved
7/31/1997
On Market Since
5/13/1997
Pharmacological Classes
Price Statistics
The NADAC for CRINONE 8% GEL has been published 146 times since Sep 25, 2019, and over the history we have for it it has risen 9.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $27.9726 per GM |
|---|---|
| All-time high | $28.0219 (Aug 12, 2026) |
| All-time low | $25.2990 (Apr 17, 2024) |
| 52-week high | $28.0219 |
| 52-week low | $26.5926 |
| Median price | $26.7506 |
| Average price | $26.5759 |
| Largest weekly change | +5.0% (Jan 14, 2026) |
| Weeks tracked | 146 |
| Tracking since | Sep 25, 2019 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the progesterone market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Allergan, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
progesterone market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Progesterone class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CRINONE 8% GEL?
The current National Average Drug Acquisition Cost (NADAC) for CRINONE 8% GEL, manufactured by Allergan, Inc., is $27.9726 per GM (NDC 00023615108), effective Sep 30, 2026.
How has the price of CRINONE 8% GEL changed over time?
Over the history we have for it, the NADAC for CRINONE 8% GEL has risen 9.6%. It has been tracked across 146 weekly CMS publications since Sep 25, 2019.
What are the highest and lowest recorded NADAC prices for CRINONE 8% GEL?
Since Sep 25, 2019, the NADAC for CRINONE 8% GEL has ranged from a low of $25.2990 (Apr 17, 2024) to a high of $28.0219 (Aug 12, 2026), with a median of $26.7506 per GM.
Are there cheaper alternatives to CRINONE 8% GEL?
No other NADAC-published product currently shares the active ingredient and strength of CRINONE 8% GEL in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures CRINONE 8% GEL?
CRINONE 8% GEL (NDC 00023615108) is labeled by Allergan, Inc., and CMS classifies it as a brand product.